At a glance
ClinicalIndex Comparison RecordPhase 2Active· 14 enrolled
Drug / intervention
BL-M02D1drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ib/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M02D1 for Injection in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Non-small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating BL-M02D1 for Non-small Cell Lung Cancer. Active but no longer recruiting, targeting 14 participants across 1 site.
Detailed Summary
Phase Ib: To explore the safety and preliminary efficacy of BL-M02D1 to further define RP2D in a variety of solid tumors such as locally advanced or metastatic non-small cell lung cancer. Phase II: To explore the efficacy of BL-M02D1 using single-agent RP2D obtained from phase I clinical studies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesChina
Collaborators--
Timeline
Phase 2ActiveOverdue
202420252026
First PostedJul 2023
Enrollment StartSep 2023
Primary CompletionDec 2025
TodayJul 2026
First PostedJul 18, 2023
Enrollment StartSep 4, 2023
Primary CompletionDec 1, 2025
TodayJul 1, 2026
Enrollment to primary: 2.2 yearsPosted 3.0 years ago
Interventions
BL-M02D1drug
Administration by intravenous infusion